BullFrog AI Holdings, Inc. is a digital biopharmaceutical company that uses artificial intelligence and machine learning to accelerate drug discovery and development for internal programs and external clients. The company develops proprietary AI/ML platforms, including bfLEAP™ (derived from Johns Hopkins University technology), which analyzes complex biomedical datasets to identify therapeutic opportunities and patient populations without requiring predefined hypotheses. The company generates revenue through three models: fee-for-service contracts with biopharmaceutical companies to analyze datasets at discovery through clinical stages, collaborative partnerships combining service fees with milestone-based payments, and by acquiring rights to failed late-stage drugs, applying its platform to identify high-responder populations, and divesting the repositioned assets to larger pharmaceutical companies. The company holds exclusive licenses to mebendazole formulations for cancer treatment and siRNA candidates for hepatocellular carcinoma and liver disease, and maintains strategic partnerships with academic institutions and disease-focused organizations to access clinical and genomic data.